Injecting drug use is the main risk of hepatitis C virus (HCV) transmission in most developed countries. HCV antiviral treatment (peginterferon-a + ribavirin) has been shown to be cost-effective for patients with no reinfection risk. We examined the cost-effectiveness of providing antiviral treatment for injecting drug users (IDUs) as compared with treating ex/non-IDUs or no treatment.
- hepatitis C
- antiviral treatment
- intravenous drug users
- reinfection risk
Martin, N. K., Vickerman, P., Miners, A., Foster, G. R., Hutchinson, S., Goldberg, D., & Hickman, M. (2012). Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology, 55(1), 49-57. https://doi.org/10.1002/hep.24656